RxDoctor Payments Data

Samantha Branson

Family · O Fallon, MONPI 1386186732

Payments from drug & device makers

$971in general payments, 2019–2025

Across 11 payments — averaging $88.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$206
  • AstraZeneca$198
  • Edwards Lifesciences$124
  • Lilly USA, LLC$107
  • Exeltis, USA Inc.$102
  • Boehringer Ingelheim$102
  • plus $132 from 2 others

What the payments were for

  • Food & beverage$970100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$971 in reported general payments places this provider in the 65th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$42,683
Medicare patients
240
Services billed
676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol42$44,765
MounjaroTirzepatide33$41,803
OzempicSemaglutide16$24,827
JardianceEmpagliflozin19$18,033
EliquisApixaban22$17,508
ArexvyRsvpref3 Antigen/As01e/Pf26$6,294
Duloxetine Hcl48$1,675
Atorvastatin Calcium172$1,054
Levothyroxine Sodium127$944
Rosuvastatin Calcium79$831
Azelastine Hcl34$669
Albuterol Sulfate HfaAlbuterol Sulfate37$631
Doxycycline Hyclate64$631
Venlafaxine Hcl ErVenlafaxine Hcl19$572
Amlodipine Besylate114$572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$198$44,76542 claims
Lilly USA, LLCMounjaro$107$41,80333 claims
Boehringer IngelheimJardiance$102$18,03319 claims
GSKArexvy$206$6,29426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,812 family providers in Missouri.

Other family in O Fallon

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →